Teva launches generic Xeloda tablets
JERUSALEM — Teva Pharmaceutical Industries will launch the generic version of Xeloda (capecitabine) tablets, 150 mg and 500 mg, in the United States. The drug is used to treat cancers that have metastasized.
Xeloda tablets, 150 mg and 500 mg had annual sales in the United States of approximately $754 million as of December 2013, according to IMS.
MPS&A’s pharmacy management system EnterpriseRx earns industry accolades
LIVONIA, Mich. — McKesson Pharmacy Systems & Automation on Friday announced that EnterpriseRx — its cloud-based, centrally hosted pharmacy management system — earned top honors as a Category Leader in the 2013 Best in KLAS: Software and Services report. KLAS, an independent healthcare research organization, reserves the Category Leader designation for vendors that lead select market segments with software solutions designed to help healthcare professionals provide better care for their patients.
“We are proud to earn KLAS’s recognition for the outstanding technology that EnterpriseRx offers the health system market,” stated Emilie Ray, VP and general manager, outpatient, MPS&A. “We believe our pharmacy management system’s strong ranking in this industry is a reflection of our commitment to provide world-class pharmacy solutions to pharmacists, physicians and patients.”
EnterpriseRx is designed to allow pharmacists to run a patient-centered business and to make a pronounced difference in the way that pharmacies are traditionally run. The system increases operational efficiencies behind the counter so that pharmacists can spend more time on clinical programs such as adherence, medication therapy management and distribution of specialty medications.
“EnterpriseRx has set its self apart in operational efficiency and support of clinical programs, but our next focus is on connectivity between providers throughout the health system,” said Nathan Mott, president MPS&A. “With the backing of McKesson and our involvement in the CommonWell Health Alliance, we are looking forward to being at the forefront of an initiative that connects pharmacy to the continuum of care.”
Lupin approved for generic Monodox, Cipro
MUMBAI and BALTIMORE — Lupin on Thursday announced that it received final approval from the Food and Drug Administration for its doxycycline capsules USP, 50 mg, 75 mg and 100 mg, which is the generic version of Aqua Pharmaceuticals’ Monodox capsules. The drug is used to treat infections caused by various microorganisms and as an adjunctive therapy in severe acne, according to the company.
The company also received FDA approval for its ciprofloxacin for oral suspension 5 g/100 mL (250 mg/5 mL) and 10 g/100 mL (500-mg/5-mL), a generic form of Cipro for oral suspension from Bayer HealthCare Pharmaceuticals. The drug is used for the treatment of infections caused by susceptible isolates of the designated microorganisms in various conditions and patient populations, the company said.
Monodox capsules had annual sales in the United States of 180.6 million for the year ending December 2013, according to IMS MAT data; Cipro oral suspension had sales of $8.6 millon.